<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92301">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01903356</url>
  </required_header>
  <id_info>
    <org_study_id>1288.22</org_study_id>
    <nct_id>NCT01903356</nct_id>
  </id_info>
  <brief_title>A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea</brief_title>
  <official_title>A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta DuoÂ® (Linagliptin/Metformin HCl, 2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/1000 mg, b.i.d) in Korean Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to monitor the safety profile of Trajenta Duo in
      Korean patients with type 2 diabetes mellitus (T2DM) in a routine clinical setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:

      PMS Observational study
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events in patients who take at least one dose of Trajenta Duo</measure>
    <time_frame>up to 26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Glucosylated Hemoglobin (HbA1c) after 24 weeks of treatment</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of treat to target effectiveness response, that is an Glucosylated Hemoglobin (HbA1c) under treatment of &lt; 6.5% after 24 weeks of treatment</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of relative effectiveness response (HbA1c lowering by at least 0.5% after 24 weeks)</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose (FPG) after 24 weeks of treatment</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Patients with T2DM</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trajenta duo</intervention_name>
    <description>Linagliptin and Metformin</description>
    <arm_group_label>Patients with T2DM</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Korean patients with T2DM
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

        Potential subjets must meet all of the following inclusion criteria to enter this trial:

          1. No previous exposure to Trajenta, Trajenta Duo

          2. Should have been started on Trajenta Duo in accordance with the approved label in
             Korea

          3. No current participation in clinical trials

          4. No metformin is inappropriate due to contraindications

          5. Must sign on the data release consent form

        Exclusion criteria:

        Individuals with any of the following characteristics will not be able to enter this
        study:

          1. Previous exposure to Trajenta, Trajenta Duo

          2. Current participation in clinical trials

          3. Patients for whom metformin is inappropriate due to contraindications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>One or multiple Investigational sites</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 21, 2017</lastchanged_date>
  <firstreceived_date>July 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
